Latest Tacrolimus Stories
HORSHOLM, Denmark, Jan.
HORSHOLM, Denmark, Jan. 6, 2011 /PRNewswire/ -- LifeCycle Pharma A/S (OMX: LCP) has as of November 23, 2010 completed its fully subscribed rights offering of 395,974,671 new shares at DKK 1.20 per share.
PITTSBURGH, Sept. 21 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S.
SHENYANG, China, Aug. 24 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products and Isotechnika Pharma Inc.
TARRYTOWN, N.Y. and TOKYO, July 28 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and Astellas Pharma Inc.
MORRISTOWN, N.J., July 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.
Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients.
DEERFIELD, Ill., March 4 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX(TM) (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT(TM) (dexlansoprazole).
A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors.
CAMBRIDGE, Mass. and TOKYO, Nov. 10 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).